Page last updated: 2024-12-05

thiazolidines

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thiazolidines are heterocyclic compounds containing a five-membered ring with a sulfur atom and a nitrogen atom. They have garnered significant attention in medicinal chemistry due to their diverse pharmacological properties, exhibiting a wide range of biological activities. Thiazolidines have been reported to possess anti-inflammatory, anti-diabetic, anti-cancer, and antimicrobial properties. Their synthesis typically involves the reaction of an amino acid with a carbonyl compound, followed by cyclization. The presence of the sulfur atom in the thiazolidine ring is responsible for its unique chemical properties, which contribute to its interactions with various biological targets. For instance, thiazolidine derivatives have been shown to inhibit enzymes involved in inflammation, such as cyclooxygenase (COX) and lipoxygenase (LOX), as well as to modulate insulin signaling pathways in the treatment of diabetes. Their potential as drug candidates has led to extensive research and development efforts, resulting in the discovery of numerous thiazolidine-based drugs currently in clinical trials or on the market. The exploration of novel thiazolidine derivatives continues to be a major area of interest in the field of medicinal chemistry, with researchers focusing on improving their efficacy, selectivity, and pharmacokinetic properties.'

Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10444
CHEMBL ID1916078
CHEBI ID50120
MeSH IDM0496444

Synonyms (33)

Synonym
CHEBI:50120 ,
504-78-9
thiazole, tetrahydro-
nsc-357911
1-thia-3-azacyclopentane
nsc357911
thiazolidine ,
inchi=1/c3h7ns/c1-2-5-3-4-1/h4h,1-3h
1,3-thiazolidine
thiazolidine, 95%
brn 0102469
ccris 4275
tetrahydrothiazole
einecs 208-002-5
AKOS005146302
T0793
CHEMBL1916078 ,
bdbm50357214
thiazolidines
i320806bkw ,
4-27-00-00009 (beilstein handbook reference)
unii-i320806bkw
nsc 357911
1,3-thiazolidine #
DTXSID10198447
mfcd00005211
CS-0006687
BCP22810
Q413761
STR04848
AMY40189
H11361
EN300-43043

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Administration of a toxic dose of precocene II (175 mg/kg) to male Sprague-Dawley rats rapidly depleted hepatic GSH, produced histopathological changes in the liver, and induced increases in serum aminotransferase activity."( Alteration of precocene II-induced hepatotoxicity by modulation of hepatic glutathione levels.
Duddy, SK; Hsia, MT, 1989
)
0.28
"Hymenoxon and helenalin are toxic sesquiterpene lactones present in the toxic range plants Hymenoxys odorata and Helenium microcephalum."( Role of glutathione in the toxicity of the sesquiterpene lactones hymenoxon and helenalin.
Hayes, MA; Kim, HL; Merrill, JC; Murray, CA; Safe, S, 1988
)
0.27
" In this investigation, we have found that sensitivity to CHCl3 correlates with the capacity of the kidney to metabolize CHCl3 to the toxic metabolite phosgene (COCl2)."( Strain and sex differences in chloroform-induced nephrotoxicity. Different rates of metabolism of chloroform to phosgene by the mouse kidney.
George, JW; Pohl, LR; Satoh, H,
)
0.13
" Pretreatment with phenobarbital enhanced the toxic response of renal cortical slices to CHCl3 in vitro as indicated by decreased p-aminohippurate and tetraethylammonium accumulation."( Mechanism of chloroform nephrotoxicity. IV. Phenobarbital potentiation of in vitro chloroform metabolism and toxicity in rabbit kidneys.
Bailie, MB; Hook, JB; Newton, JF; Smith, JH, 1984
)
0.27
" Adverse events were observed in two patients on moguisteine, three on codeine 15 mg, and five on codeine 30 mg."( The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough.
Barnabè, R; Berni, F; Clini, V; Pirrelli, M; Pisani Ceretti, A; Robuschi, M; Rossi, M; Sestini, P; Tana, F; Vaghi, A, 1995
)
0.29
" Two groups could be distinguished: PMA, EMT and MMC are one order of magnitude more toxic than MC, MN and MA."( Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human proximal tubular cells.
Bohets, HH; D'Haese, PC; De Broe, ME; Dierickx, PJ; Nouwen, EJ; Van der Biest, I; Van Landeghem, GF; Van Thielen, MN, 1995
)
0.29
" These results indicate that the no-effect dose of rentiapril in rats by three months oral administration is 30 mg/kg in female and 125 mg/kg in male, and suggest that, like other ACE-inhibitors, this compound also has a toxic potential to affect renal tissues."( Toxicity study of the angiotensin converting enzyme inhibitor rentiapril in rats.
Aono, H; Ikuse, T; Okahara, A; Takase, K, 1995
)
0.29
" No serious adverse events were reported."( Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases.
Allegra, L; Aversa, C; Cazzola, M; Clini, V; Dal Negro, R; Maiorano, V; Tana, F, 1993
)
0.29
" Spermine proved highly toxic and growth rates were reduced compared with controls when even ."( Toxicity and growth-promoting potential of spermine when fed to chicks.
Smith, TK; Sousadias, MG, 1995
)
0.29
" The air concentration at which such adverse effects can first be observed is presently a subject of controversy."( Neurotoxicity of long-term low-level exposure to carbon disulphide: results of questionnaire, clinical neurological examination and neuropsychological testing.
Angerer, J; Bickel, A; Claus, D; Drexler, H; Lehnert, G; Neundörfer, B; Reinhardt, F; Ulm, K, 1997
)
0.3
" Incubation of the cells with CP (2 mM and 10 mM) drastically attenuated the GSH and cysteine depletion caused by toxic concentrations of paracetamol (1 mM and 5 mM)."( 2-Methyl-thiazolidine-2,4-dicarboxylic acid protects against paracetamol induced toxicity in human liver derived HepG2 cells.
Rommelspacher, H; Włodek, L, 1997
)
0.3
"Amino acids (AA) which were proposed as an alternative osmotically active agents in dialysates are toxic to human peritoneal mesothelial cells (HPMC) due to disturbance of the antioxidant-oxidant balance in cells by reducing level of glutathione."( In vitro effect of glutathione precursors on cytotoxicity of amino acids to human mesothelial cells.
Grzybowski, AE, 1999
)
0.3
" Because OTZ reduced the toxic effects of GDP on mesothelial cells, this compound may improve biocompatibility of peritoneal dialysis fluids."( L-2-oxothiazolidine-4-carboxylic acid reduces in vitro cytotoxicity of glucose degradation products.
Breborowicz, A; Oreopoulos, D; Polubinska, A; Pyda, M; Witowski, J, 2004
)
0.32
" Only 2 patients discontinued MAS063DP due to an adverse event."( A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
Abramovits, W; Boguniewicz, M, 2006
)
0.33
"MAS063DP cream was confirmed to be a safe and effective treatment for mild to moderate atopic dermatitis in adults."( A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults.
Abramovits, W; Boguniewicz, M, 2006
)
0.33
" Cytotoxicity and cell proliferation assays were performed to elucidate the adverse effects of formaldehyde on U2OS cells."( Cytotoxicity of formaldehyde on human osteoblastic cells is related to intracellular glutathione levels.
Chang, YC; Ho, YC; Huang, FM, 2007
)
0.34
"The secondary and adverse effects when biguanides, alpha-glycosidase inhibitor or thiazolidine derivative was used with sulphonylurea agent (SU) as compared with those with SU alone in Type 2 diabetes patients by using Systematic Review."( Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review.
Eto, M; Katsuyama, S; Miura, M; Mohri, K; Mouri, K; Mukai, J; Shoji, T; Suzuki, T; Tada, H; Watanabe, Y, 2007
)
0.34
"Cytotoxicity, cell proliferation and collagen synthesis assays were performed to elucidate the toxic effects of CHX on the human osteoblastic cell line U2OS."( Cytotoxicity of chlorhexidine on human osteoblastic cells is related to intracellular glutathione levels.
Chang, YC; Chou, MY; Hu, CC; Lee, SS; Lee, TH, 2010
)
0.36
" The incidence of adverse events and drug-related adverse events was similar among groups."( Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
Eto, T; Inoue, S; Kadowaki, T, 2012
)
0.38
" The incidence of adverse events and adverse drug reactions was similar in each group."( Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Kadowaki, T; Kondo, K, 2013
)
0.39
"Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients."( Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T, 2014
)
0.4
" The incidence rates of adverse events and adverse drug reactions, including hypoglycaemia, during the double-blind randomized period were similar in both groups."( Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki, T; Kondo, K, 2014
)
0.4
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
"To investigate whether it is safe to use leucogen tablets 60 mg three times per day (180 mg for a day) and whether this regimen could reduce the incidence of febrile neutropenia caused by chemotherapy."( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia.
Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014
)
0.4
" Treatment-emergent adverse events were attributable to complications of myelosuppressive chemotherapy or the primary disease (i."( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia.
Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014
)
0.4
"This study suggested that leucogen tablets 60mg three times per day (180mg for a day) are safe and could be effective for preventing febrile neutropenia in patients with chemotherapy."( Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia.
Cao, J; Huang, XE; Liu, J; Qian, ZY; Shi, L; Wang, L; Wu, XY; Xu, X, 2014
)
0.4
" The incidence of adverse events was similar between the groups."( Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Cha, BY; Chul Jang, HC; Chung, CH; Han, KA; Jang, WI; Kim, KA; Kim, MK; Ku, BJ; Lee, HW; Lee, MK; Park, IB; Park, JY; Park, KS; Rhee, EJ; Woo, AC, 2015
)
0.42
" Safety measures included adverse events (AEs), adverse reactions and hypoglycemia."( Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
Iijima, H; Kadowaki, T; Katoh, M; Marubayashi, F; Yokota, S, 2015
)
0.42
"Incidences of AEs and adverse reactions were similar among the teneligliptin monotherapy group and all combination therapy groups except the combination with sulfonylurea."( Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies.
Iijima, H; Kadowaki, T; Katoh, M; Marubayashi, F; Yokota, S, 2015
)
0.42
" Sixteen adverse events (AEs) were reported, 12 of them of mild intensity."( Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.
Dingemanse, J; Guérard, N; Hoch, M; Zwingelstein, C, 2016
)
0.43
" The incidence of hypoglycaemia and adverse events were not significantly different between the two groups."( Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Ahn, CW; Cho, YW; Chung, CH; Han, KA; Hong, S; Jang, HC; Ku, BJ; Lee, CB; Lee, MK; Moon, MK; Park, CY; Park, SW; Son, HS, 2016
)
0.43
"Among novel 4-thiazolidinone derivatives, ID 3288 was most toxic toward rat glioma C6 cells, even compared with doxorubicin."( Putative anticancer potential of novel 4-thiazolidinone derivatives: cytotoxicity toward rat C6 glioma in vitro and correlation of general toxicity with the balance of free radical oxidation in rats.
Biletska, LP; Boiko, NM; Grytsyna, II; Klyuchivska, OY; Lesyk, RB; Panchuk, RR; Stoika, RS; Zіmenkovsky, BS; Коbylinska, LI, 2016
)
0.43
" In addition, the in vitro cytotoxicity activity of thiazolidin-4-ones against Vero cells was also performed and four compounds (4a, 4c, 4d and 4f) showed no toxic effect at 500 μg/mL."( 2-Aryl-3-(2-morpholinoethyl)thiazolidin-4-ones: Synthesis, anti-inflammatory in vivo, cytotoxicity in vitro and molecular docking studies.
Almeida, WP; Cunico, W; Dos Anjos Berwaldt, G; Fischer, G; Neto, AC; Pires Gouvea, D; Sakata, RP; Vasconcellos, FA, 2016
)
0.43
" In conclusion, this work reports at least four compounds (5b, 5e, 5g and 6e) with potential anti-tumor effect against glioblastoma multiform cell presenting activity at low concentrations and safe profile of cytotoxicity."( Thiazolidin-4-ones from 4-(methylthio)benzaldehyde and 4-(methylsulfonyl)benzaldehyde: Synthesis, antiglioma activity and cytotoxicity.
Azambuja, JH; Braganhol, E; Cunico, W; da Silva, CEH; da Silva, DS; de Carvalho, TR; Frizzo, CP; Soares, MSP; Spanevello, RM; Zimmer, GC, 2016
)
0.43
" Other endpoints included changes in fasting plasma glucose, body weight, proinsulin/C-peptide ratio, homeostatic model assessment 2-%B and adverse events."( Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2017
)
0.46
" The safety endpoint was the incidence of adverse events (AEs)."( Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2018
)
0.48
" The incidence of adverse events was 53."( Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
Gouda, M; Kadowaki, T; Kondo, K; Miyayama, K; Sasaki, N; Terata, R; Yokota, S, 2017
)
0.46
" The incidence of adverse events was similar in both groups (55."( Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
Gouda, M; Iijima, H; Inagaki, N; Kadowaki, T; Kaneko, G; Kondo, K; Maruyama, N; Nakanishi, N; Nishimura, K; Watanabe, Y, 2018
)
0.48
" Survey items included demographics, treatments, adverse drug reactions (ADRs), and laboratory variables."( Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
Haneda, M; Iijima, H; Ito, H; Kadowaki, T; Kimura, M; Matsukawa, M; Sasaki, K; Ueno, M; Yamakura, T, 2018
)
0.48
" No clinically relevant changes in safety parameters were shown and there were no serious adverse events."( Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Coates, S; Gotteland, JP; Lorch, U; Marchand, L; Pohl, O; Täubel, J, 2018
)
0.48
"Administration of OBE022 was safe and had favourable pharmacokinetic characteristics and no clinically relevant interaction with food."( Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Coates, S; Gotteland, JP; Lorch, U; Marchand, L; Pohl, O; Täubel, J, 2018
)
0.48
" Both gliptins were well-tolerated with no difference in the number of adverse events."( A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Kasthuri, S; Mohan, V; Poongothai, S; Ramu, M, 2019
)
0.51
" Both gliptins were found to be safe and well-tolerated in Indian patients with T2DM."( A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Kasthuri, S; Mohan, V; Poongothai, S; Ramu, M, 2019
)
0.51
" Collected data included demographics, treatments, adverse drug reactions (ADRs) and laboratory variables."( Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
Haneda, M; Ito, H; Kadowaki, T; Matsukawa, M; Sasaki, K; Yamada, Y, 2020
)
0.56
" It is of specific concern as a toxic intermediate in the design of engineered pathways involving methanol oxidation or formate reduction."( Thioproline formation as a driver of formaldehyde toxicity in Escherichia coli.
Bar-Even, A; Bruner, SD; Fiehn, O; Folz, JS; Hanson, AD; He, H; Li, Q; Patterson, JA; Wilson, MA, 2020
)
0.56
" Collected data included demographics, treatments, adverse drug reactions (ADRs), and laboratory variables."( Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Haneda, M; Ito, H; Kadowaki, T; Sasaki, K; Yamada, Y, 2020
)
0.56
" We found that there was no clear difference in the number of adverse drug reactions among three age subgroups: < 65 years, ≥ 65 to < 75 years, or ≥ 75 years, although the incidence of serious adverse drug reactions was higher in elderly patients than in patients aged < 65 years."( Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
Haneda, M; Ito, H; Kadowaki, T; Sasaki, K; Yamada, Y, 2020
)
0.56
" Safety was assessed by the incidence of adverse events and adverse drug reactions."( Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Ji, L; Li, W; Liu, J; Lu, W; Ma, J; Takayanagi, G; Wang, Y; Xiao, X; Yang, J; Zeng, J; Zhang, X, 2021
)
0.62
" The adverse event and adverse drug reaction incidence rates, including hypoglycemia, were similar in both groups."( Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
Ji, L; Li, W; Liu, J; Lu, W; Ma, J; Takayanagi, G; Wang, Y; Xiao, X; Yang, J; Zeng, J; Zhang, X, 2021
)
0.62
" At each follow-up visit, peak expiratory flow (PEF) and asthma symptom score and medicine adverse effects were recorded."( Efficacy and Safety of Pidotimod in Persistent Asthma: A Randomized Triple-Blinded Placebo-Controlled Trial.
Deglurkar, R; Mathew, JL; Singh, M, 2022
)
0.72
" Secondary outcomes were PEF at each follow-up visit, asthma symptom score at each visit, change in asthma symptom score at 12 weeks, and adverse event profile."( Efficacy and Safety of Pidotimod in Persistent Asthma: A Randomized Triple-Blinded Placebo-Controlled Trial.
Deglurkar, R; Mathew, JL; Singh, M, 2022
)
0.72
" There were no significant adverse effects observed."( Efficacy and Safety of Pidotimod in Persistent Asthma: A Randomized Triple-Blinded Placebo-Controlled Trial.
Deglurkar, R; Mathew, JL; Singh, M, 2022
)
0.72
" There was no significant difference between the groups in the rate of adverse events (placebo-teneligliptin group, n = 3 [6."( Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
Kim, JH; Lee, BW; Lee, M; Lee, WJ, 2022
)
0.72
" In this study, we investigated the toxic effects of AZD1208 on mouse oocytes."( Toxic effects of AZD1208 on mouse oocytes and its possible mechanisms.
Meng, TG; Ouyang, YC; Sun, QY; Wang, ZB; Xue, Y; Yan, FZ; Yue, W; Zhang, HY; Zhang, XR, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"Based on previous animal and on preliminary human results a further human study was performed in order to confirm the relevant pharmacokinetic parameters and the lack of accumulation of letosteine after repeated administrations."( Pharmacokinetic study of 14C-letosteine in man after oral intake and steady-state.
Donath, A; Llull, JB; Schifflers, MH; Wermeille, M, 1991
)
0.28
" As a consequence plasma half-life was prolonged considerably in some patients."( Effects of cardiac failure on the pharmacokinetics of the diuretic tizolemide.
Beermann, B; Edelstam, C, 1984
)
0.27
"The pharmacokinetic studies on pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) a new biological response modifier, following intravenous, intramuscular or oral administrations in rats and dogs are reported in this paper."( Pharmacokinetics of pidotimod in rats and dogs.
Coppi, G; Silingardi, S, 1994
)
0.29
"Pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6), a new biological response modifier, was investigated in 3 different pharmacokinetic experiments in healthy volunteers."( Pharmacokinetics and oral bioavailability of pidotimod in humans.
Coppi, G; Mailland, F; Silingardi, S, 1994
)
0.29
" No differences in absorption, excretion and pharmacokinetic parameters was evident between old volunteers and the youngs of a previous work."( Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients.
Biffi, M; Coppi, G; Mailland, F; Silingardi, S; Spotti, D, 1994
)
0.29
" Thus, for later moguisteine pharmacokinetic evaluations the investigation of the plasma concentration-time curve and the urinary excretion of the sole racemic M1 through non-stereospecific analytical methods may suffice in most cases."( Stereoselective pharmacokinetics of moguisteine metabolites in healthy subjects.
Bernareggi, A; Carlesi, RM; Castoldi, D; Ceserani, R; Crema, A; Ratti, D; Ratti, E; Renoldi, MI; Tognella, S,
)
0.13
"In 13 subjects with ALS, we studied the safety and pharmacokinetic properties of Procysteine, a cysteine prodrug that increases levels of intracellular glutathione."( The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis.
Brown, RH; Cudkowicz, ME; Ellis, T; Gwilt, PR; Hayden, DL; Sexton, PM; Whalen, J, 1999
)
0.3
" The terminal half-life (t(1/2)) values ranged between 9 and 31 h on day 1 and between 7 and 18 h on day 14."( Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
De Nanteuil, G; Guez, D; Heidet, V; Jochemsen, R; Morain, P; Robin, JL, 2000
)
0.31
" The pre-study validation results, as well as the in-study quality control (QC) data obtained, demonstrate the feasibility of the assay for pharmacokinetic evaluation of the compounds in different species and confirm the robustness of the assay for routine use."( Quantitative analysis of dipeptidyl peptidase inhibitor P32/98 and its main metabolite in rat, dog, mouse, monkey, human plasma and human urine using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic evaluation.
Demuth, HU; Girault, J; Gourinchas, E; Meyer, A, 2003
)
0.32
"Methods used included the in-vitro inhibition of cyclooxygenase-1 and -2, in-vivo evaluation of anti-inflammatory activity by air pouch and peritonitis models and the pharmacokinetic profile after intravenous (3 mg/kg) and oral (3 and 6 mg/kg) dosing to rats."( Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.
da Silva, TG; Dalla Costa, T; de Lima, Mdo C; Galdino, SL; Pitta, Ida R; Uchôa, Fde T, 2009
)
0.35
"A selective, rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed for the first time to determine pidotimod in human plasma and applied to a pharmacokinetic study."( High-performance liquid chromatography-tandem mass spectrometry for the determination of pidotimod in human plasma and its application to a pharmacokinetic study.
Li, F; Liu, W; Lu, S; Qin, F; Xiong, Z; Zhang, Y, 2009
)
0.35
"A selective, rapid and sensitive hydrophilic interaction liquid chromatography-tandem mass spectrometry (HILIC-MS/MS) method was developed for the first time to determine adefovir in human plasma and applied to a pharmacokinetic study."( Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of adefovir in human plasma and its application to a pharmacokinetic study.
Li, F; Qin, F; Qin, T; Xiong, Z; Yang, S; Zhang, Y, 2010
)
0.36
" The pharmacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover of the new cathepsin K inhibitor, ONO-5334, were investigated in a multiple ascending dose, phase 1 study."( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012
)
0.38
" To provide robust support for its pharmacokinetic and clinical studies, a rapid and sensitive method based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) was developed and validated for the analysis of letosteine in plasma samples."( Development of a novel LC-MS/MS method for the determination of letosteine in human plasma and its application on pharmacokinetic studies.
Cao, C; Chen, H; Liu, X; Qian, Z; Tang, W; Wang, J; Wen, X; Yuan, S; Zheng, H; Zhu, Y, 2011
)
0.37
" We studied the pharmacokinetic and pharmacodynamic characteristics of KR-66223 in rats, monkeys, and dogs to predict PK/PD profiles in humans."( Pharmacokinetics and pharmacodynamics of KR-66223, a novel DPP-4 inhibitor.
Ahn, JH; Ahn, SH; Bae, MA; Choi, SH; Kim, MS; Kwon, HJ; Lee, KR; Lee, SH; Rhee, SD; Song, IS; Song, JS, 2012
)
0.38
" The method was successfully applied to the pharmacokinetic study after oral administration of single-dose and multiple-dose of moguisteine tablets in healthy Chinese subjects."( Determination of the active metabolite of moguisteine in human plasma and urine by LC-ESI-MS method and its application in pharmacokinetic study.
Bu, F; Guo, R; Liu, X; Song, H; Teng, Y; Wang, B; Wei, C; Yuan, G; Zhang, R; Zhao, W, 2012
)
0.38
" Validated method was applied to analyze rat plasma samples obtained from a pharmacokinetic study."( LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Ajjala, DR; Bhyrapuneni, G; Kandikere, V; Muddana, NR; Nirogi, R, 2013
)
0.39
"The purpose of the study was clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers using sustained release (SR) formulations with different pharmacokinetic (PK) patterns, and identify the optimal SR formulation."( Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Deacon, S; Hashimoto, Y; Honda, N; Sekiya, N; Tanaka, M; Yamamoto, M, 2014
)
0.4
" There was no significant difference in PK and pharmacodynamic potency (IC50 ) between Caucasian and Japanese."( Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Deacon, S; Hasegawa, C; Honda, N; Ieiri, I; Nagase, S; Ogawa, M; Ohno, T; Ohyama, M; Small, M; Umemura, T, 2014
)
0.4
" The pharmacokinetic parameters (Cmax, Tmax, AUC, terminal t½, apparent total plasma clearance, and Vd during the terminal phase) of teneligliptin on days 1 and 11 were calculated."( Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
Akimoto, K; Davies, M; Hayashi, Y; Jürgen Heuer, H; Kawaguchi, A; Kinoshita, S; Nakamaru, Y; Sekine, M; Thompson, J; Yamazaki, H, 2014
)
0.4
"This review considers the pharmacokinetic profile, adverse effects and drug interactions of DPP-4 inhibitors."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" However, DPP-4 inhibitors have certain differences in their pharmacokinetic properties that may be associated with different clinical effects and adverse event profiles."( The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Athyros, VG; Elisaf, MS; Filippatos, TD, 2014
)
0.4
" The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) model to elucidate in detail the pharmacokinetics of teneligliptin."( Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Emoto, C; Nakamaru, Y; Shimizu, M; Yamazaki, H, 2015
)
0.42
" To determine whether differences in in vitro and in vivo efficacy were due to unfavorable pharmacokinetic properties of BG-323, we conducted a pharmacokinetic evaluation of this small molecule."( Murine Efficacy and Pharmacokinetic Evaluation of the Flaviviral NS5 Capping Enzyme 2-Thioxothiazolidin-4-One Inhibitor BG-323.
Bullard, KM; Geiss, BJ; Gullberg, RC; Keenan, SM; Soltani, E; Steel, JJ, 2015
)
0.42
" Pharmacokinetic outcomes were the AUC0-τ and Cmax of metformin and teneligliptin when administered alone or in combination."( Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
Akimoto, K; Davies, M; Hayashi, Y; Hisanaga, N; Jürgen Heuer, H; Nakamaru, Y, 2015
)
0.42
" All 20 subjects in each group were included in the safety analyses, and 19 subjects in each group were included in the pharmacokinetic analyses."( Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
Akimoto, K; Davies, M; Hayashi, Y; Hisanaga, N; Jürgen Heuer, H; Nakamaru, Y, 2015
)
0.42
"The aim of the present study is to explore pharmacokinetic and protein binding characteristics of a novel dipeptidylpeptidase-4 (DPP-4) inhibitor, teneligliptin in rats using an ultra high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS)."( Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor - Teneligliptin in rats using liquid chromatography-tandem mass spectrometry.
Satheeshkumar, N; Shantikumar, S; Srinivas, R, 2015
)
0.42
" Cmax and tmax values of ponesimod were comparable across all groups in both studies."( Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor Modulator.
Dingemanse, J; Guérard, N; Hoch, M; Zwingelstein, C, 2016
)
0.43
" Geometric least square mean ratios for Cmax in subjects with mild and moderate hepatic impairment were 25% and 38% higher than in healthy subjects, and those for AUC0-∞ were 46% and 59% higher than in healthy subjects, respectively."( Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
Faisst, N; Halabi, A; Hinrichsen, H; Maatouk, H; Siegler, KE, 2014
)
0.4
"This study was aimed at exploring the accuracy of population pharmacokinetic method in evaluating the bioequivalence of pidotimod with sparse data profiles and whether this method is suitable for bioequivalence evaluation in special populations such as children with fewer samplings."( Advantage of population pharmacokinetic method for evaluating the bioequivalence and accuracy of parameter estimation of pidotimod.
Chen, J; He, Y; Huang, J; Li, M; Lv, Y; Wang, J; Wang, K; Xu, L; Yang, J; Zheng, Q, 2016
)
0.43
"The 90% confidence intervals (CIs) for AUC0-12h, AUC0-∞, and Cmax were 97."( Advantage of population pharmacokinetic method for evaluating the bioequivalence and accuracy of parameter estimation of pidotimod.
Chen, J; He, Y; Huang, J; Li, M; Lv, Y; Wang, J; Wang, K; Xu, L; Yang, J; Zheng, Q, 2016
)
0.43
"The population pharmacokinetic modeling method was used to assess the bioequivalence of two pidotimod formulations with relatively few sampling points and further validated the bioequivalence of the two formulations."( Advantage of population pharmacokinetic method for evaluating the bioequivalence and accuracy of parameter estimation of pidotimod.
Chen, J; He, Y; Huang, J; Li, M; Lv, Y; Wang, J; Wang, K; Xu, L; Yang, J; Zheng, Q, 2016
)
0.43
"In the present study, a simple, rapid and reliable ultrahigh-performance liquid chromatography-tandem mass spectrometric (UHPLC-MS/MS) method was developed and validated to determine simultaneously epalrestat (EPA) and puerarin (PUE) in rat plasma for evaluation of the pharmacokinetic interaction of these two drugs."( Simultaneous determination of epalrestat and puerarin in rat plasma by UHPLC-MS/MS: Application to their pharmacokinetic interaction study.
Bo, Y; Sun, H; Wu, X; Xiong, Z; Zhang, M; Zhao, L; Zhou, M, 2017
)
0.46
" The mean half-life of OBE002 ranged between 8 and 11 h following administration of a single dose and 22-29 h after multiple doses."( Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Coates, S; Gotteland, JP; Lorch, U; Marchand, L; Pohl, O; Täubel, J, 2018
)
0.48
"Administration of OBE022 was safe and had favourable pharmacokinetic characteristics and no clinically relevant interaction with food."( Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.
Coates, S; Gotteland, JP; Lorch, U; Marchand, L; Pohl, O; Täubel, J, 2018
)
0.48
" The compound has high solubility, high chemical, microsomal, and hepatocyte stability, and favorable pharmacokinetic properties and was confirmed to induce human neutrophil mobilization and to inhibit lipolysis in murine adipocytes."( Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.
Bolognini, D; Ejsing, CS; Ekberg, JH; Hansen, AH; McKenzie, CJ; Milligan, G; Rexen Ulven, E; Sergeev, E; Sprenger, RR; Ulven, T, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
" The drug did not show antimicrobial or antifungal activities nor interact with some of the most common therapeutics (antibiotics, tolbutamide, pentobarbital, antihypertensives, chlorothiazide, warfarin, non-steroidal antiinflammatory agents)."( General pharmacology of pidotimod and testing for drug interactions.
Coppi, G; Falcone, A; Ieva, G; Manzardo, S; Pinzetta, A, 1994
)
0.29
"The aim of this study was to investigate the effect of long-term treatment with the dipeptidyl peptidase inhibitor P32/98 and its combination with rosiglitazone on blood glucose control and islet of Langerhans histology in male Zucker diabetic fatty (ZDF) rats, when treatment begins before or after the development of overt diabetes."( Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E, 2005
)
0.33
"To gain new insight into the functional interaction between dendritic cells and methionine encephalin (MENK) combined with pidotimod (PTD), we have analyzed the effect of MENK plus PTD on the morphology, phenotype and functions of murine bone-marrow derived dendritic cells (BMDCs) in vitro."( Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs).
Meng, Y; Plotnikoff, NP; Shan, F; Wang, E; Wang, Q; Zhang, Z, 2013
)
0.39
"The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy."( Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Cha, BY; Chul Jang, HC; Chung, CH; Han, KA; Jang, WI; Kim, KA; Kim, MK; Ku, BJ; Lee, HW; Lee, MK; Park, IB; Park, JY; Park, KS; Rhee, EJ; Woo, AC, 2015
)
0.42
"Objective To compare the clinical effectiveness of lipoic acid combined with epalrestat versus lipoic acid in treating diabetic peripheral neuropathy(DPN)."( Lipoic Acid Combined with Epalrestat versus Lipoic Acid in Treating Diabetic Peripheral Neuropathy:A Meta-analysis.
Lin, HX; Lu, YK; Wang, XT; Xu, SA, 2017
)
0.46
" Epalrestat combined with α-lipoic acid (ALA) is the most frequent combine therapy used in the DPN researches."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
"This review will evaluate the total effective rate, nerve conduction velocity, TCSS, TSS, and safety of ALA combined with epalrestat for patients with DPN, compare with epalrestat alone."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
"Our study will provide evidence to assess whether epalrestat combined with ALA is an optional treatment for patients with DPN."( The clinical efficacy of epalrestat combined with α-lipoic acid in diabetic peripheral neuropathy: Protocol for a systematic review and meta-analysis.
Jin, Y; Lin, H; Wang, X; Xu, S; Zhang, R, 2018
)
0.48
" For the first time, were combined an in silico approaches like molecular docking and ab initio computational simulation based on Density Functional Theory (DFT) to explain the drug-drug interaction mechanism of aforementioned chemotherapy ligands with the transmembrane ligand extrusion binding domains (TMDs) of ABCB1."( Modeling drug-drug interactions of AZD1208 with Vincristine and Daunorubicin on ligand-extrusion binding TMD-domains of multidrug resistance P-glycoprotein (ABCB1).
Almeida, DV; da Silva Nornberg, BF; de Oliveira, PV; Fagan, SB; González-Durruthy, M; Marins, LF; Marques, MB; Oliveira, BR, 2019
)
0.51
"Sodium-glucose cotransporter 2 inhibitor combined with dipeptidyl peptidase-4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy."( Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Aoki, S; Atsumi, T; Cho, KY; Kameda, H; Kawata, S; Kurihara, Y; Miya, A; Miyoshi, H; Nagai, S; Nakamura, A; Nishimoto, N; Nomoto, H; Omori, K; Shigesawa, I; Sugawara, H; Takeuchi, J; Taneda, S; Tsuchida, K; Yanagiya, S; Yokoyama, H, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" The results show a good absorption rate of letosteine since about 90% of the dose was found in the urine."( Pharmacokinetic study of 14C-letosteine in man after oral intake and steady-state.
Donath, A; Llull, JB; Schifflers, MH; Wermeille, M, 1991
)
0.28
" Brain proteolytic enzymes may limit the bioavailability of [3H]MK-771."( Metabolism of the TRH analog L-pyro-2-aminoadipyl-L-histidyl-[3H]-L-thiazolidine-4-carboxamide (MK-771) in gut and brain tissue of rats: the implications for its bioavailability.
Arison, BH; Duncan, CA; Nutt, RF; Ramjit, HG; Rosegay, A; Veber, DF; Vickers, S,
)
0.13
" Bioavailability was 100% in the intramuscular route and 27% in the oral route."( Pharmacokinetics of pidotimod in rats and dogs.
Coppi, G; Silingardi, S, 1994
)
0.29
" The intake of a standard meal before pidotimod administration, either as sachet or as ampoule, reduced the bioavailability of the drug, probably due to an interference at the absorption level."( Effect of food on the bioavailability of pidotimod in healthy volunteers.
Caravaggi, M; Crema, A; Crema, F; D'Angelo, L; De Ponti, F, 1994
)
0.29
") administrations to obtain the disposition characteristics and bioavailability of this new anti-AIDS drug."( Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
Kiriyama, A; Kiso, Y; Mimoto, T; Takada, K, 1993
)
0.29
" Analysis of urinary TTCA proved to be useful both for establishing the in vivo release of CS2 by dithiocarbamate containing compounds and for evaluating the bioavailability of CS2."( The measurement of 2-thiothiazolidine-4-carboxylic acid as an index of the in vivo release of CS2 by dithiocarbamates.
Amarnath, K; Amarnath, V; Graham, DG; Johnson, DJ; Valentine, WM,
)
0.13
" The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals."( Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Fukazawa, T; Hayashi, H; Kato, R; Kiso, Y; Mimoto, T; Misawa, S; Nojima, S; Sato, H; Shintani, M; Takaku, H; Terashima, K; Ueno, T, 1999
)
0.3
" (14)C-telmesteine was rapidly absorbed after oral dosing (20 and 50 mg kg(-1)) with an oral bioavailability of >90% both in male and female rats."( Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
Kim, DH; Lee, J; Rhee, SW; Son, J, 2003
)
0.32
"The aim of this study was to estimate in vivo permeability and bioavailability of epalrestat and newly synthesized compounds with possible therapeutic activity as aldose enzyme inhibitors (ARIs)."( Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro.
Demopoulos, VJ; Kristl, A; Levstik, L; Sturm, K, 2006
)
0.33
" Diminished antioxidant capacity increases vascular superoxide levels, which reduce NO bioavailability and promote peroxynitrite generation."( Vascular oxidative stress and nitric oxide depletion in HIV-1 transgenic rats are reversed by glutathione restoration.
Dikalov, S; Guidot, DM; Hart, CM; Jones, DP; Kleinhenz, DJ; Kline, ER; Liang, B; Sutliff, RL, 2008
)
0.35
" Currently, there are no reports regarding the bioavailability of latrunculol A in vivo."( Development and validation of a rapid method for the detection of latrunculol A in plasma.
Amagata, T; Crews, P; Johnson, TA; Media, J; Shaw, J; Tenney, K; Valeriote, FA, 2010
)
0.36
" These findings suggest that KR66222 undergoes a significant first pass effect, which may serve to decrease the bioavailability of KR66222."( In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223.
Ahn, HJ; Ahn, JH; Bae, MA; Kim, KB; Kim, MS; Liu, KH; Shin, JG; Song, IS, 2011
)
0.37
"Water-in-oil-in-water (w/o/w) double emulsions are potential for enhancing oral bioavailability of drugs with high solubility and low permeability, but their industrial application is limited due to the instability."( Self-double-emulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability.
Hu, Z; Qi, X; Wang, L; Zhang, J; Zhu, J, 2011
)
0.37
"The aims of this study were to prepare fine pidotimod-containing water-in-oil-in-water (W/O/W) double emulsions and to investigate the possibility of those emulsions as a delivery system for promoting the oral bioavailability of pidotimod."( Water-in-oil-in-water double emulsions: an excellent delivery system for improving the oral bioavailability of pidotimod in rats.
Qi, X; Wang, L; Zhu, J, 2011
)
0.37
"5h and bioavailability of 85%."( NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile.
Chaudhary, S; Dube, A; Kothari, V; Sachan, N; Upasani, CD, 2012
)
0.38
" Bioavailability was found to be 90 ± 14% for epalrestat in male wistar rats."( LC-MS/MS method for the quantification of aldose reductase inhibitor-epalrestat and application to pharmacokinetic study.
Ajjala, DR; Bhyrapuneni, G; Kandikere, V; Muddana, NR; Nirogi, R, 2013
)
0.39
" Prolonged circulation half-life and tumor site bioavailability were achieved for both the drugs with the developed approach."( Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
Banala, VT; Dwivedi, M; Gautam, S; Marwaha, D; Mishra, PR; Sharma, M; Sharma, S; Shukla, RP; Urandur, S, 2019
)
0.51
"We investigated the dermal bioavailability and antioxidative properties of a sunscreen formulation containing two antioxidants, oxothiazolidine (OTZ) and δ-tocopheryl glucoside (DTG)."( Sustained effect of two antioxidants (oxothiazolidine and δ-tocopheryl glucoside) for immediate and long-term sun protection in a sunscreen emulsion based on their different penetrating properties.
Bacqueville, D; Bessou-Touya, S; Duplan, H; Génies, C; Jacques, C; Jeanjean-Miquel, C; Noizet, M; Tourette, A, 2021
)
0.62
"After topical application to a hair follicle-derived reconstructed human epidermis (RHE) model, followed by solar-simulated radiation, kinetics of bioavailability and antioxidative responses were measured over 24 h."( Sustained effect of two antioxidants (oxothiazolidine and δ-tocopheryl glucoside) for immediate and long-term sun protection in a sunscreen emulsion based on their different penetrating properties.
Bacqueville, D; Bessou-Touya, S; Duplan, H; Génies, C; Jacques, C; Jeanjean-Miquel, C; Noizet, M; Tourette, A, 2021
)
0.62
"The two antioxidants had different bioavailability profiles: OTZ was rapidly and extensively absorbed, whereas DTG was slowly absorbed and converted to δ-tocopherol."( Sustained effect of two antioxidants (oxothiazolidine and δ-tocopheryl glucoside) for immediate and long-term sun protection in a sunscreen emulsion based on their different penetrating properties.
Bacqueville, D; Bessou-Touya, S; Duplan, H; Génies, C; Jacques, C; Jeanjean-Miquel, C; Noizet, M; Tourette, A, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Only diet was given in between dosing days to ensure baseline levels of NAA excretion."( Influence of fruit and vegetable juices on the endogenous formation of N-nitrosoproline and N-nitrosothiazolidine-4-carboxylic acid in humans on controlled diets.
Helser, MA; Hotchkiss, JH; Roe, DA, 1992
)
0.28
", shifted the dose-response curves of platelet-activating factor-induced platelet aggregation to the right in a parallel manner."( Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
Hara, H; Horie, M; Mase, T; Nagaoka, H; Saito, M; Tomioka, K; Yamada, T,
)
0.13
" with 950 mg/kg of OTC 4 hours before dosing with 5-FU."( Effects of L-2-oxothiazolidine-4-carboxylate, a cysteine pro-drug, on teratogenicity of 5-fluorouracil in mice.
Deguchi, T; Mataki, Y; Naya, M; Noguchi, M; Yasuda, M, 1990
)
0.28
" Airway responsiveness was determined from the slopes of dose-response curves of SRL vs."( YM461, a PAF antagonist, blocks antigen-induced late airway responses and airway hyperresponsiveness in allergic sheep.
Abraham, WM; Ahmed, A; Garrido, R; Stevenson, JS; Tomioka, K, 1989
)
0.28
" Although there was no obvious effect upon fertility there was an increased incidence of total litter loss at 500 mg/kg/d and mean pup weights to day 21 post partum were reduced at this dosage and at 100 mg/kg/d with delays in the attainment of some of the developmental landmarks."( Reproductive toxicity studies of rentiapril.
Barton, SJ; Clark, R; Cozens, DD; Hughes, EW; Offer, JM; Yamamoto, Y, 1987
)
0.27
" Pretreatment with 4 mumol/kg of 1-NP shifted the entire dose-response curve for head-twitching induced by quipazine (0."( Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents.
Schechter, LE; Simansky, KJ, 1988
)
0.27
" Daily oral dosing of hydralazine (2 mg/kg/day) for 14 weeks had little or no effect on SBP, but potentiated the antihypertensive effect of SA446."( [Antihypertensive effects of SA446, hydralazine and the combination on renal hypertensive rats and spontaneously hypertensive rats by long-term treatment].
Iso, T; Nakata, K; Nishimura, K; Takada, T; Yamauchi, H, 1986
)
0.27
" N-Acetyl-L-cysteine, L-2-oxothiazolidine-4-carboxylate or the L- or D-isomers of 2-methylthiazolidine-4-carboxylate were administered to male mice immediately after a hepatotoxic dosage of acetaminophen (5."( Effects of cysteine pro-drugs on acetaminophen-induced hepatotoxicity.
Hazelton, GA; Hjelle, JJ; Klaassen, CD, 1986
)
0.27
" A dose-response relationship was established for the formation of NPRO in rats in vivo, after concurrent administration of various concentrations of the precursors, L-proline and sodium nitrite."( Monitoring endogenous nitrosamine formation in man.
Bartsch, H; Ohshima, H, 1984
)
0.27
" A similar dose-response relationship was found in young flies treated with TCA for 1 week and then deprived of food and water, a procedure found to induce accelerated physiological aging."( Accelerated aging of fasted Drosophila. Preservation of physiological function and cellular fine structure by thiazolidine carboxylic acid (TCA).
Ballard, RC; Binnard, R; Economos, AC; Miquel, J; Philpott, DE, 1982
)
0.26
" After oral dosing (10 mg/rat), PB had an inhibiting effect on the excretion rate of TTCA."( Effect of cytochrome P450 isozyme induction and glutathione depletion on the metabolism of CS2 to TTCA in rats.
Aitio, A; Elovaara, E; Kivistö, H; Riihimaki, V, 1995
)
0.29
"5 times the maximum dosage intended for clinical use."( Toxicological evaluation of pidotimod.
Amico-Roxas, M; Bertè, F; Bussi, R; Coppi, G; Gnemi, P; Harling, RJ; Mailland, F; Manzardo, S; Massey, JE; Spencer-Briggs, DJ, 1994
)
0.29
" During the first 8-day phase (D0-D8), 68 patients received 800 mg pidotimod orally (one sachet) twice daily and an antibiotic treatment (amoxycillin plus clavulanic acid: 1 g twice daily), while 69 patients received placebo (one sachet) and antibiotic according to the same dosage schedule."( Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchitis.
Cirianni, C; Dolcetti, A; Fugazza, L; Moreo, G; Orlandi, O; Piacenza, G; Pozzi, E; Rampulla, C; Scarpazza, G, 1994
)
0.29
" Increases in whole-blood glutathione were observed in the highest dosage group after 6 weeks of therapy."( A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects.
Borum, PR; Chance, M; Emgushov, RT; Jackson, JB; Kalayjian, RC; Mayer, KH; Skowron, G; Spell, SA; Webb, LS; Yen-Lieberman, B, 1994
)
0.29
" After repeated dosing (12-15 days), moguisteine did not induce tolerance in either guinea-pigs or dogs."( Moguisteine: a novel peripheral non-narcotic antitussive drug.
Borghi, A; Ceserani, R; Dalla Rosa, C; Gallico, L; Tognella, S, 1994
)
0.29
" In one study, acute high dosage survivorship was compared for approximately equimolar cysteine dosages of L-cysteine and Procysteine."( Toxicity evaluations of L-cysteine and Procysteine, a cysteine prodrug, given once intravenously to neonatal rats.
Glosson, JA; Goldberg, DI; Madsen, DC; Rowe, WB; White, RD; Wilson, DM, 1993
)
0.29
" The method was specific and no immunoreactive material other than parent drug was detectable in plasma from dosed volunteers."( Determination of MK-852, a new fibrinogen receptor antagonist, in plasma and urine by radioimmunoassay.
Barrish, A; Fernandez-Metzler, C; Gilbert, JD; Hand, EL; Hichens, M; Olah, TV; Yuan, AS, 1993
)
0.29
" Metabolites found circulating in the plasma of rats dosed with HP236 were identical to those produced in vitro using rat liver microsomes or S9 fractions; however, LC/MS analysis of rat urine extract showed that the metabolite profile was different than that obtained from plasma or from in vitro extracts."( Metabolism of an atypical antipsychotic agent, 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2, 5,5-trimethyl-4-thiazolidinone (HP236).
Hrib, N; Jurcak, J; Mutlib, AE, 1996
)
0.29
" Further studies are needed to investigate optimal dosage scheme, mechanism of action, and interference with anti-tumor activity and prevention of long-term side effects of cyclophosphamide."( Protective effects of L-2-oxothiazolidine-4-carboxylate treatment on cyclophosphamide-induced cystitis in rats.
Gordon, D; Leaf, C; Rice, D; Safron, J; White, R, 1997
)
0.3
"A randomized double-blind, placebo-controlled study was conducted in 37 asymptomatic HIV-infected individuals (mean CD4 count 707 cells/mm3) to characterize the safety, pharmacokinetics, and effect on blood thiols of three dosage levels of a cysteine prodrug, L-2-oxothiazolidine-4-carboxylic acid (OTC; Procysteine; Clintec Technologies, Deerfield, IL)."( A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus.
Barditch-Crovo, P; Borum, P; Buier, R; Goldberg, D; Kalayjian, RC; Lederman, M; Lietman, P; Noe, D; Rowe, WB; Skowron, G, 1998
)
0.3
" Dose-response studies show a good correlation between inhibition of actin polymerization and increased degranulation."( The role of actin microfilaments in the down-regulation of the degranulation response in RBL-2H3 mast cells.
Apgar, JR; Frigeri, L, 1999
)
0.3
" Peptidomimetics 3 and 4 were evaluated in vivo as modulators of apomorphine-induced rotational behavior in the 6-hydroxydopamine-lesioned rat model of hemiparkinsonism, and each affected the rotational behavior in a bell-shaped dose-response relationship producing increases of 95 +/- 31% (0."( Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Gleason, WB; Johnson, RL; Khalil, EM; Mishra, RK; Nair, VD; Ojala, WH; Pradhan, A, 1999
)
0.3
" In vivo studies in rats and dogs dosed orally and intravenously confirmed the stereoselective metabolism of tazofelone observed in vitro."( Stereoselective metabolism of tazofelone, an anti-inflammatory bowel disease agent, in rats and dogs and in human liver microsomes.
Clay, MP; Hanssen, BR; Lindstrom, TD; Surapaneni, SS, 1999
)
0.3
" The results of this preliminary study indicate that analysis of TTCA, although regarded as an established biomarker, can give biases and thus negatively interfere with inferred dose-effect or dose-response relationships in occupational epidemiology."( Preliminary external quality assessment for the biological monitoring of carbon disulfide with urinary 2-thiothiazolidine-4-carboxylic acid.
Braeckman, L; Bulat, P; Daemen, E; de Bacquer, D; van Risseghem, M; Vanhoorne, M, 1999
)
0.3
" Procysteine enters CSF after both IV and oral dosing and accumulates to significant levels in CSF."( The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis.
Brown, RH; Cudkowicz, ME; Ellis, T; Gwilt, PR; Hayden, DL; Sexton, PM; Whalen, J, 1999
)
0.3
" Peptidomimetics 3-5 each affected rotational behavior in a bell-shaped dose-response relationship producing maximal increases of 44% (1 microgram/kg,ip), 56% (0."( Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Gleason, WB; Johnson, RL; Khalil, EM; Mishra, RK; Ojala, WH; Pradhan, A, 1999
)
0.3
" The concentrations of the different antioxidants were: 1 mM for thioproline and N-acetylcysteine and 5 microM for ascorbic acid and alpha-tocopherol, which induced a maximum effect in our previous dose-response experiments."( Effects in vitro of several antioxidants on the natural killer function of aging mice.
Correa, R; De la Fuente, M; Del Rio, M; Ferrández, MD, 1999
)
0.3
" The results obtained in elderly healthy subjects indicated that S 17092 is suitable for once-daily dosing without any serious adverse events."( Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study.
De Nanteuil, G; Guez, D; Heidet, V; Jochemsen, R; Morain, P; Robin, JL, 2000
)
0.31
" (14)C-telmesteine was rapidly absorbed after oral dosing (20 and 50 mg kg(-1)) with an oral bioavailability of >90% both in male and female rats."( Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat.
Kim, DH; Lee, J; Rhee, SW; Son, J, 2003
)
0.32
" Whereas supraoptimal FcepsilonRI engagement decreased degranulation, which is known as a bell-shaped dose-response curve, such inhibitory effect was not observed with FcalphaR engagement."( Functionality of the IgA Fc receptor (FcalphaR, CD89) is down-regulated by extensive engagement of FcepsilonRI.
Matsui, T; Nunomura, S; Ra, C; Shimokawa, T; Yoshimaru, T, 2008
)
0.35
"Methods used included the in-vitro inhibition of cyclooxygenase-1 and -2, in-vivo evaluation of anti-inflammatory activity by air pouch and peritonitis models and the pharmacokinetic profile after intravenous (3 mg/kg) and oral (3 and 6 mg/kg) dosing to rats."( Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.
da Silva, TG; Dalla Costa, T; de Lima, Mdo C; Galdino, SL; Pitta, Ida R; Uchôa, Fde T, 2009
)
0.35
"The erratic absorption of PG15 observed after oral dosing could explain the lack of anti-inflammatory dose dependency."( Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.
da Silva, TG; Dalla Costa, T; de Lima, Mdo C; Galdino, SL; Pitta, Ida R; Uchôa, Fde T, 2009
)
0.35
" Pharmacokinetic investigation of 8bo in beagle dogs suggests that the compound is suitable for once daily dosing in humans."( 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.
Abele, S; Binkert, C; Bolli, MH; Bravo, R; Buchmann, S; Bur, D; Gatfield, J; Hess, P; Kohl, C; Mangold, C; Mathys, B; Menyhart, K; Müller, C; Nayler, O; Scherz, M; Schmidt, G; Sippel, V; Steiner, B; Strasser, D; Treiber, A; Weller, T, 2010
)
0.36
" The perfusion system presented here is a simple, inexpensive device suited for analysis of drug dose-response and regeneration of single cells and arrays of cells."( Microfluidic perfusion system for culturing and imaging yeast cell microarrays and rapidly exchanging media.
Juncker, D; Li, H; Mirzaei, M; Nazarova, E; Pla-Roca, M; Safavieh, M; Safavieh, R; Vogel, J, 2010
)
0.36
" Interestingly, reducing the dosage of cofilin by half or expressing a phospho-mimetic mutant form, S3E, partially rescues the migration and protrusion defects of Rac-deficient border cells."( Regulation of cofilin phosphorylation and asymmetry in collective cell migration during morphogenesis.
Chen, J; Laski, F; Luo, J; Wan, P; Wu, J; Zhang, L, 2011
)
0.37
" Multiple dosing with ONO-5334 100 mg resulted in considerable suppression of bone resorption markers with no appreciable effects on bone formation markers (B-ALP, OC) or osteoclast number (TRAP5b)."( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012
)
0.38
" These levels were consistently decreased below pre-dose levels by repeated oral dosing with ONO-5334 for 7 days."( Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Hashimoto, Y; Kawabata, K; Kawada, N; Kayasuga, R; Kunishige, A; Mori, H; Nakanishi, Y; Nishikawa, S; Ochi, Y; Sugitani, M; Tanaka, M; Yamada, H, 2011
)
0.37
" Among the tested, several representative compounds demonstrated in vivo efficacy after oral dosing in rats."( Synthesis and evaluation of novel modified γ-lactam prostanoids as EP4 subtype-selective agonists.
Kambe, T; Maruyama, T; Minamoto, C; Nagase, T; Nakai, H; Ogawa, S; Sakata, K; Toda, M, 2012
)
0.38
"Dipeptidyl peptidase IV (DPP-4) inhibition is suitable mechanism for once daily oral dosing regimen because of its low risk of hypoglycemia."( Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for t
Abe, Y; Akahoshi, F; Anabuki, J; Fukuda, S; Hayashi, Y; Ishige, T; Ishii, S; Kishida, H; Kitajima, H; Kiuchi, S; Kosaka, K; Masutomi, N; Miyaguchi, I; Murozono, T; Nabeno, M; Nakamaru, Y; Nakamura, M; Sakashita, H; Sekiguchi, S; Shima, K; Soejima, A; Sonda, S; Takashina, Y; Takeuchi, M; Tanaka, Y; Tsutsumiuchi, R; Ueda, N; Utsumi, H; Yoshida, K; Yoshida, T, 2012
)
0.38
"To assess the efficacy, safety and dose-response relationship of once-daily teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise."( Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Kadowaki, T; Kondo, K, 2013
)
0.39
" Repeated SRT dosing did not significantly affect PK, although C 24h increased slightly."( Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M, 2015
)
0.42
" Exposure to 50 or 100 pulses of 10 ns duration and 150 kV/cm in a single dosage approximately lowers average CHO cell elastic modulus by half, whereas latrunculin lowers it more than 75%."( Disruption of the actin cortex contributes to susceptibility of mammalian cells to nanosecond pulsed electric fields.
Ibey, BL; Kuipers, M; Roth, C; Thompson, GL; Tolstykh, G, 2014
)
0.4
"Biological cells can be characterized as "soft matter" with mechanical characteristics potentially modulated by external cues such as pharmaceutical dosage or fever temperature."( Chemoenvironmental modulators of fluidity in the suspended biological cell.
Maloney, JM; Van Vliet, KJ, 2014
)
0.4
"Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women than evening dosing."( Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Deacon, S; Dijk, DJ; Eastell, R; Greenwood, A; Sharpe, J; Small, M; Tanimoto, M; Yamada, H; Yuba, M, 2016
)
0.43
" Cardiovascular parameters included blood pressure, total, LDL and HDL cholesterol, triglycerides, C-reactive protein dosed in serum with high sensitivity (HsCRP), N-terminal pro-brain natriuretic peptide, and albuminuria/creatininuria ratio (UACR)."( No evidence of cardiovascular toxicity in workers exposed below 5 ppm carbon disulfide.
Domergue, J; Haufroid, V; Lison, D, 2016
)
0.43
" Groups B, C and D remained on the normal dosage of aluminum chloride for three more weeks (59 days)."( Effect of D-ribose-L-cysteine on aluminum induced testicular damage in male Sprague-Dawley rats.
Adeleke, O; Falana, B; Orenolu, M; Osinubi, A; Oyewopo, A, 2017
)
0.46
"Most treatments for diabetic eye conditions rely on systemic (oral) or intravitreal administration, and there is still a demand of efficient and comfortable ocular dosage forms."( Epalrestat-loaded silicone hydrogels as contact lenses to address diabetic-eye complications.
Alvarez-Lorenzo, C; Alvarez-Rivera, F; Concheiro, A, 2018
)
0.48
" Safety of the dosing schedules was assessed based on physical examination, recording of adverse events, 12-lead electrocardiography, and laboratory tests."( Single- and multiple-dose pharmacokinetics of the peripheral non-narcotic antitussive moguisteine in healthy Chinese volunteers.
Feng, P; Gou, ZP; Wang, Y; Xiang, J; Zheng, L, 2019
)
0.51
" Accurate dose-response curves could be generated, and we found that mild oxidative stress delayed multiple stages of virus production, but eventually infection processes occurred with approximately the same amplitudes."( Kinetics of Mimivirus Infection Stages Quantified Using Image Flow Cytometry.
Dadosh, T; Minsky, A; Mutsafi, Y; Porat, Z; Yaakov, LB, 2019
)
0.51
" These methods are also used for routine quality control analysis of teneligliptin in pharmaceutical dosage forms."( Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
Hatware, K; Patil, K; Sharma, R; Sharma, S, 2020
)
0.56
"We firstly showed that high dosage of Pidotimod could be an effective and safe to reduce the PFAPA attacks in children."( Proposal for a new therapeutic high dosage of Pidotimod in children with periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome: a randomized controlled study.
Barone, P; Filosco, F; Finocchiaro, GG; Giugno, A; Leonardi, S; Manti, S; Papale, M; Parisi, GF, 2020
)
0.56
" This study shows that the proper dosing interval and drug dose both are important to eradicate the viral infection."( A Model for SARS-CoV-2 Infection with Treatment.
Al Basir, F; Chatterjee, AN, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
thiazolidineA saturated organic heteromonocyclic parent comprising a five-membered ring with a sulfur at position 1 and a nitrogen at either position 2 or 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,385)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990370 (10.93)18.7374
1990's475 (14.03)18.2507
2000's1010 (29.84)29.6817
2010's1250 (36.93)24.3611
2020's280 (8.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 73.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index73.46 (24.57)
Research Supply Index8.22 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index133.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (73.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials160 (4.51%)5.53%
Reviews121 (3.41%)6.00%
Case Studies18 (0.51%)4.05%
Observational1 (0.03%)0.25%
Other3,244 (91.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]